AstraZeneca stock trades flat as GLP-1 elecoglipron advances to Phase III trials

Traders Union
All News
Financial News
AstraZeneca rises 0.09% to GBX13,484 today

Highlights

AstraZeneca received FDA approval for Truqap to treat PTEN-deficient metastatic prostate cancer, strengthening its US oncology portfolio.
Pipeline advancements include elecoglipron entering Phase III for diabetes and regulatory wins for Imfinzi, Lokelma, and Calquence across Europe and the UK.
AZN/GBX trades in a bullish short-term structure with mixed momentum signals, expecting a range between GBX12,458.63 and GBX14,509.37 in the near term.

Oncology approvals and trial progress drive pipeline momentum amid US market gains

AstraZeneca has secured US Food and Drug Administration approval for Truqap (capivasertib) in combination with abiraterone and prednisone to treat adult patients with PTEN-deficient metastatic prostate cancer, a regulatory milestone that expands its oncology presence in the high-value US market, according to GxP News. The company's oral GLP-1 receptor agonist elecoglipron has also progressed to Phase III clinical trials following strong Phase IIb efficacy data, signaling advancement in its diabetes portfolio, as Insider Monkey reports. Additional product and indication access was marked by NICE endorsement for Imfinzi’s perioperative use in stomach cancer and the expansion of Lokelma’s coverage for NHS patients, alongside the completion of a Phase I trial for a new cholesterol-lowering combination and a European Commission label extension for Calquence in leukemia regimens.

Overbought signals clash with fading trend strength as volatility stays low

Technically, AZN is positioned above the MA-20 at GBX13,309.45 and MA-50 at GBX13,426.51, while remaining under the MA-200 at GBX13,601.80. Immediate support is defined by the Ichimoku Kijun at GBX12,495.00. Momentum indicators present a mixed picture: while the MACD is Neutral, the ADX signals Strong Sell, suggesting weak trend strength. The RSI at 58.43 leans mildly bullish, but Stoch RSI, CCI, and BBP all show overbought conditions, indicating short-term buyer dominance with a potential risk of exhaustion. The Awesome Oscillator remains Neutral, and price action is characterized by low volatility near daily highs, with a slight negative gap versus the previous close. These conflicting signals reflect a divergence between recent price gains and waning underlying momentum.

Sideways price drift expected as breakout odds hinge on bullish follow-through

Over the next several days, AZN is likely to fluctuate within a volatility band ranging from GBX12,458.63 to GBX14,509.37. There is a 57% chance of an upward move, while downward scenarios are less probable in the short term. The baseline expectation is for sideways price drift within this corridor; sustained bullish momentum could prompt a breakout above resistance, whereas renewed selling might see the price breach immediate support and target lower levels.

Anton Kharitonov, analyst at Traders Union, sees AstraZeneca’s news flow as broadly positive, with key regulatory approvals and pipeline progress supporting sentiment. However, he notes that technical momentum is weakening and overbought conditions have emerged near resistance levels. The overall setup points to range-bound action, with any sustained upside needing confirmation. "With mixed momentum and price stalling near resistance, I remain cautious and will wait for a breakout or a clear reversal signal before taking a stance on AZN."

Earlier, analysts noted that AstraZeneca shares remained under persistent selling pressure despite positive regulatory and clinical developments, resulting in a broadly cautious technical outlook. With the latest approvals and late-stage pipeline progress now matched by improving near-term momentum, traders should monitor the potential for a sustained upside break if volatility persists above GBX14,509.37 resistance.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.